Submission of outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Novelix Pharmaceuticals (formerly Trimurthi Limited), held on October 23, 2025, approved two key items. First, it allotted 16,61,000 equity shares of Rs. 10 face value at Rs. 20 each (including Rs. 10 premium) to 19 allottees upon conversion of equivalent warrants, bringing in Rs. 2.49 crore from warrant holders who paid the remaining 75% of the issue price. The company's paid-up equity capital rose from Rs. 14.48 crore to Rs. 16.14 crore, with total shares now at 1,61,41,000. Second, the board appointed Ms. Sridevi Belide (DIN: 10455373), an MBBS-qualified medical professional, as an Additional Non-Executive Non-Independent Director effective the same date.
The warrant conversion increases share dilution by roughly 11.5% and brings in additional capital from existing warrant holders, while the appointment of a promoter-related director strengthens promoter influence on the board and is relevant for shareholders tracking governance composition.